UBS Group’s 2ndVote Life Neutral Plus ETF LYFE Stock Holding History

UBS Group’s Portfolio LYFE Stock Details LYFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-801	Closed	-$26.8K	–	10299
2023 Q2	$26.8K	Buy	801 +791	+7,910%	+$25K	﹤0.01%	6753
2023 Q1	$314	Sell	10 -719	-99%	-$22.1K	﹤0.01%	9079
2022 Q4	$21.1K	Buy	+729	New	+$21.7K	﹤0.01%	7583
2022 Q3	–	Sell	-434	Closed	-$12K	–	11352
2022 Q2	$12K	Buy	434 +370	+578%	+$11.1K	﹤0.01%	7722
2022 Q1	$2K	Sell	64 -139	-68%	-$4.43K	﹤0.01%	9741
2021 Q4	$7K	Buy	+203	New	+$6.58K	﹤0.01%	9200
2021 Q3	–	Sell	-2	Closed	–	–	10349
2021 Q2	$0	Buy	2 +1	+100%	+$30	﹤0.01%	10023
2021 Q1	$0	Buy	+1	New	+$27	﹤0.01%	9661

Other funds holding LYFE

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

UBS Group's LYFE Position: Q3 2023 in Review

UBS Group sold out of 2ndVote Life Neutral Plus ETF (LYFE) in Q3 2023, closing a stake of 801 shares — an estimated $26.8K sold.

UBS Group first reported a position in LYFE in Q1 2021 and held it in 8 quarters. The position peaked at $26.8K in Q2 2023. 1 fund tracked by Wall St. Rank holds LYFE as of Q3 2023.

UBS Group reported no remaining 2ndVote Life Neutral Plus ETF position as of Q3 2023 after selling out during the quarter.
UBS Group sold 801 2ndVote Life Neutral Plus ETF shares in Q3 2023, an estimated $26.8K.
UBS Group first reported a position in 2ndVote Life Neutral Plus ETF in Q1 2021 and held it in 8 quarters.
UBS Group's 2ndVote Life Neutral Plus ETF position peaked at $26.8K in Q2 2023.
1 fund tracked by Wall St. Rank held 2ndVote Life Neutral Plus ETF as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.